Evidence map›Paper›PMID 35202403›Full record

ReviewPLoS neglected tropical diseases2022

Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities.

Bright K Ocansey, Chris Kosmidis, Martin Agyei, Améyo M Dorkenoo, Olusola O Ayanlowo, Rita O Oladele, Tchin Darre, David W Denning

Open access · goldAbstract readReview
In one paragraph

Review in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. AIDS research and human retroviruses · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Histoplasmosis.Infectious disease clinics of North America · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Genotypic diversity, virulence, and molecular genetic tools inMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  14. One health (Amsterdam, Netherlands) · 2024
    Article
  15. Frequency of fungal pathogens in autopsy studies of people who died with HIV in Africa: a scoping review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024
    Article
  16. Histoplasmosis in Solid Organ Transplantation.Journal of fungi (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Acute pulmonary histoplasmosis: a case series from an outbreak in Southeastern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Bright K OcanseyDivision of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Chris KosmidisDivision of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.ORCID 0000-0003-0662-1265
Martin AgyeiDepartment of Internal Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Améyo M DorkenooDepartment of Biology and Basic Sciences, Faculty of Health Sciences, University of Lomé, Lomé, Togo.ORCID 0000-0002-1030-7757
Olusola O AyanlowoDepartment of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria.ORCID 0000-0002-1134-3813
Rita O OladeleDepartment of Medical Microbiology & Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria.ORCID 0000-0003-1488-3345
Tchin DarreDepartment of Pathology, University Teaching Hospital of Lomé, Lomé, Togo.
David W DenningDivision of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.ORCID 0000-0001-5626-2251
Manchester Academic Health Science Centre · GBUniversity of Lagos · NGKwame Nkrumah University of Science and Technology · GHTogolese Ministry of Health · TGUniversity of Lomé · TG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHistoplasmosis is a chronic granulomatous disease caused by the thermally dimorphic fungus Histoplasma capsulatum. The 2 variants Histoplasma capsulatum var. capsulatum (Hcc) and Histoplasma capsulatum var. duboisii (Hcd) causes infection in humans and commonly termed classical or American histoplasmosis and African histoplasmosis, respectively. Histoplasma capsulatum var. farciminosum (Hcf) affects equines. In recent times, there have been heightened sensitization on fungal infections such as histoplasmosis in Africa, aimed at improving awareness among relevant stakeholders, particularly healthcare workers. This effort is expected to be paralleled with increased detection of both classical and African histoplasmosis, which has remained underdiagnosed over the years. In this narrative review, we describe the current perspectives of histoplasmosis in Africa, identify knowledge gaps, and suggest research priorities.

methodsA PubMed, Google Scholar, and Africa Journal Online (AJOL) literature search was conducted for studies on histoplasmosis in Africa between 2000 and 2020. Histoplasmosis essays in medical mycology textbooks were also consulted. This narrative review was prepared from the data gathered.

findingsIn the past 2 decades, histoplasmosis in general has seen a relative increase in case detection in some Africa countries, probably attributable to the gradually increasing medical mycology advocacy efforts in Africa. Histoplasmosis cases are dominated by African histoplasmosis mostly in Western and Central Africa, while classical histoplasmosis is more common in Southern and Northern Africa. Although both classical and African histoplasmosis are common in Africa, the latter is more restricted to Africa, and cases outside the continent usually have a travel history to the continent. Despite the clinical and laboratory difference between African histoplasmosis and classical histoplasmosis, it is not straightforward to distinguish them. The typical manifestation of African histoplasmosis is the appearance of lesions affecting the skin, bones, and lymph nodes and unusually linked to human immunodeficiency virus (HIV)/AIDS. By contrast, classical histoplasmosis mostly affects the lungs and is often associated with immunosuppression, mainly HIV/AIDS. The present perspectives of histoplasmosis in Africa highlight unclear details on the true burden, strain diversity, infection route and genetic basis of African histoplasmosis, availability of specie-specific diagnostic tools, and compliance with recommended antifungal therapy. These knowledge gaps represent research questions that require scientific exploration.

conclusionsDespite a subtle increase in identifying histoplasmosis cases in Africa, it remains underdiagnosed and neglected in some parts of the continent. Increasing awareness and training among healthcare workers, bridging diagnostic and therapeutic gaps, and encouraging more research in Africa are crucial to improve the current perspectives of histoplasmosis in Africa.

Indexed as

Health Knowledge, Attitudes, PracticeAfricaAnimalsAwarenessHistoplasmaHistoplasmosisHumansResearch

Identifiers

PMID35202403
PMCPMC8870498
OpenAlexW4213443807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.